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Atherosclerosis is a lipid deposition disease that eventually leads to myocardial infarction, stroke, and ischemic
gangrene. Furthermore, it is a chronic inflammatory condition characterized by smooth muscle cell proliferation,
apoptosis, necrosis, fibrosis, and local inflammation. The atherosclerotic process is initiated when cholesterol-
containing low-density lipoproteins accumulate in the intima and thereby activate the endothelium. Leukocyte
adhesion molecules and chemokines contribute to monocyte recruitment, which in turn deteriorates atherosclero-
sis. Therefore, inflammation plays a key role in all stages of atherosclerosis progression. Anti-inflammatory cy-
tokines ameliorate the disease, whereas pro-inflammatory cytokines accelerate atherosclerosis progression. In-
flammatory markers are widely used to control the disease, and anti-inflammatory molecules are therapeutic tar-
gets for atherosclerotic diseases. Here, we review the potential role of the inflammatory system in accelerated
atherosclerosis of cardiovascular diseases and several endocrine disorders and address drug discovery based on
anti-inflammatory strategies in these diseases.
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Figure　2　Cell-specific mechanisms underlying atheroprotective effect of IGF-1. (Adapted 
from reference 21)





















Figure　4　Key molecular mechanisms involved in immune cell dysfunction associated with 


























Figure　5　sTNF-R1 levels in cured Cushing’s syndrome
(CS) patients without coronary calcifications [Agatston
score (AS) = 0] and those with coronary calcifications (AS 
> 0) and the normal reference values. *p < 0.05 between
AS = 0 and reference values, between AS > 0 and refer-






































































Table　1　Single correlation analyses with organ damage indices.  (Adapted from reference 27)
Variables
CAVI UAE eGFR hsCRP
ρ p ρ p ρ p ρ p
Age 0.762 <0.001 0.067 0.512 －0.542 <0.001 0.210 0.033
Sex 0.06 0.574 －0.049 0.631 －0.141 0.129 0.060 0.547
BMI －0.245 0.17 0.114 0.472 0.113 0.417 0.463 0.003
Blood pressure and pulse rate
SBP －0.010 0.928 0.278 0.007 0.029 0.760 －0.036 0.728
DBP －0.146 0.182 0.109 0.299 0.147 0.123 －0.19 0.064
Pulse rate 0.114 0.319 0.352 0.001 －0.093 0.353 －0.131 0.223
Urinary test
UAE 0.305 0.007 ― ― －0.011 0.914 0.055 0.602
Na 0.012 0.930 0.130 0.294 0.222 0.061 0.157 0.190
K 0.281 0.030 0.290 0.017 －0.006 0.958 0.163 0.176
Na/K －0.141 0.283 －0.005 0.969 0.251 0.034 0.041 0.733
Blood tests
Hemoglobin 0.027 0.807 －0.166 0.109 0.020 0.839 0.036 0.728
Creatinine 0.175 0.097 －0.01 0.921 －0.737 <0.001 0.078 0.432
eGFR －0.433 <0.001 －0.011 0.914 ― ― －0.101 0.312
Uric acid 0.224 0.034 0.045 0.662 －0.285 0.002 0.319 0.001
hsCRP 0.164 0.144 0.055 0.602 －0.101 0.312 ― ―
BNP 0.063 0.574 0.027 0.798 －0.086 0.388 －0.035 0.731
Albumin －0.185 0.093 －0.156 0.133 0.066 0.502 0.003 0.979
Na 0.175 0.105 0.177 0.084 －0.190 0.044 0.921 0.360
K 0.149 0.170 －0.312 0.002 －0.143 0.130 0.171 0.088
Na/K －0.076 0.429 0.333 0.001 0.123 0.196 －0.164 0.102
HbA1c 0.309 0.005 0.120 0.248 －0.026 0.793 0.361 <0.001
LDL-chol －0.001 0.993 －0.034 0.743 －0.122 0.199 0.173 0.082
HDL-chol 0.132 0.225 －0.123 0.228 －0.018 0.851 －0.381 <0.001
Triglyceride 0.072 0.504 0.049 0.633 －0.088 0.352 0.316 0.001
RAAS components
PRA 0.106 0.377 0.128 0.255 0.006 0.953 －0.009 0.938
PAC 0.048 0.685 0.165 0.134 －0.113 0.266 0.009 0.935
s(P)RR 0.305 0.004 0.253 0.012 －0.249 0.008 0.349 <0.001
CAVI, cardio-ankle vascular index; eGFR, estimated glomerular filtration rate; hsCRP, high-sensitivity C-reactive protein; 
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; UAE, urinary albumin excretion; 
BNP, brain natriuretic peptide; HbA1c, hemoglobin A1c; LDL-chol, low-density lipoprotein cholesterol; HDL-chol, high-
density lipoprotein cholesterol; RAAS, renin-angiotensin-aldosterone system; PRA, plasma renin activity; PAC, plasma al-
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